Company Overview: Prestige Consumer Healthcare Inc.

Business Focus

Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells, and distributes over-the-counter (OTC) health and personal care products. The products are sold primarily through mass merchandisers, drugstores, grocery stores, dollar stores, convenience stores, club stores, and e-commerce platforms in North America (United States and Canada), Australia, and other international markets.

Core Business Activities

• Product Development: Creating and innovating brand name OTC health and personal care products.
• Manufacturing: Outsourcing production to third-party manufacturers, with some products made in their own Lynchburg, Virginia facility. They also operate a manufacturing facility in Victoria, Australia.
• Marketing & Sales: Employing advertising campaigns, brand extensions, product line expansions, and marketing support to grow and maintain market share.
• Distribution: Broad retail distribution network, utilizing third-party logistics providers, with warehousing in Clayton, Indiana.
• Acquisition Growth: Growing through acquisitions of well-established brands from consumer and pharmaceutical companies, as well as private equity firms. Notable recent acquisition includes rights to Hydralyte in all jurisdictions except the U.S. in 2025 and assets from Akorn Operating Company LLC in 2022.
• International Expansion: International sales accounted for 15.6% of total revenues in 2025, with efforts to expand brands into new global markets.

Key Products & Market Position

• Major Brands: These include BC, Goody's (analgesics), Boudreaux's Butt Paste (dermatologicals), Chloraseptic (sore throat relief), Clear Eyes (eye/ear care), Compound W (wart removal), Debrox (ear wax removal), DenTek (oral care), Dramamine (motion sickness), Fleet (gastrointestinal), Gaviscon (upset stomach), Luden’s (cough drops), Monistat (women’s health), Nix (lice/parasite treatments), Summer’s Eve (feminine hygiene), Fess (nasal saline), Hydralyte (oral rehydration), and others.
• Market Leadership: Numerous brands hold number one or strong market positions, with approximately 83% of total revenue generated by brands with a top market position in 2025.

Financial Summary

• Revenue (2025): The company's net revenues are primarily generated from North American OTC products (about 84.4%) and international markets (about 15.6%).
• Shareholders & Stock: As of May 1, 2025, the company had approximately 49.4 million shares of common stock outstanding. Its market value was approximately $3.532 billion.
• Revenue Concentration: Top customers include Walmart (19%) and Amazon (14%). The company’s top ten customers, including these, account for a large and potentially growing share of total sales.
• Employees: The company employs approximately 600 employees globally—about 82% in the U.S., 16% in Australia and Asia, and 2% in Europe. 59% are salaried employees, and 41% are hourly workers. The workforce is 55% female and 45% male, with no unionized employees.
• Share Repurchases: The company has a share buyback program announced in May 2024, with up to $300 million of stock repurchased. During the first quarter of 2025, it bought back 137,724 shares at an average price of roughly $84.94 per share.

Other Notable Data

• Properties: Headquarters in Tarrytown, NY; manufacturing in Lynchburg, VA; Australia facility; warehousing in Clayton, Indiana.
• Regulatory & Industry: The company operates under extensive U.S. federal and foreign regulations, including FDA, FTC, EPA, and foreign authorities. It owns trademarks and patents, though none are material individually.
• Market Strategy: Focus on diversified trusted brands, effective marketing, expanding distribution channels, international growth, and strategic acquisitions to sustain long-term growth.

Note: The summary strictly encapsulates provided data—no projections or hypotheticals are included.